# Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Source: https://onco.cc/trials/nct01582672/  
OnCo record `nct01582672` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.

## Summary

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma is a phase 3 interventional study registered as NCT01582672 by Argos Therapeutics, with 462 participants enrolled, started 2012-11. Conditions recorded: Advanced Renal Cell Carcinoma, Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Interventions recorded: Standard Treatment and AGS-003.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01582672
- Phase: 3
- Setting: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
- Sponsor: Argos Therapeutics
- Enrolled: 462

## Sources

- ClinicalTrials.gov NCT01582672: https://clinicaltrials.gov/study/NCT01582672

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct01582672.json